6 ms·

Does they mean they never read it before approving it?

by mrfusion 5y ago

lame-robot-hoax 5y ago
Why would it?
geoduck14 5y ago
I think that is a given
modriano 5y ago
Should they have delayed the emergency authorization of the vaccines until these 330,000 pages had all been reviewed and redacted? It would have cost hundreds of thousands of lives, but I can't see any benefit from that course of action.
- gfodor 5y ago
  Should they delay the FOIA release until these 330,000 pages had all been reviewed and redacted? I don’t think the answer to either of these questions are “no”, though ofc the standard could vary.
- Reuzel 5y ago
  emergency authorization != approval. These shenanigans show that the approval can't have been based on all the information. They should have delayed the approval, at least until Phase III trial officially ended.
  - modriano 5y ago
    How many lives would that have cost, though, and for what benefit? The size of the sample that had already received the vaccine without issue made it basically impossible [0] for there to have been an unexpected danger. And without approval, the govt couldn't mandate federal employees take the vaccine, and that mandate has saved tens of thousands of lives. [0] https://en.m.wikipedia.org/wiki/Power_of_a_test https://en.m.wikipedia.org/wiki/Power_of_a_test
noduerme 5y ago
I'm assuming whoever made the decision read the summary. The majority of those "pages" are probably just raw data. Most of it is probably each experimental patient's temperature and blood pressure, each time they got checked, one page at a time.
mattkrause 5y ago
I'd bet that no one person has read all 329,000 pages, but I would bet that somebody looked at almost any given page. I'm hedging a bit on "any" because a New Drug Application is supposed to contain "the whole story of the drug." As a result, it includes the original and translated copies of any non-English publications related to the drug. It includes case reports for every participant who died during the trial, including in the placebo group. It includes information on related patents and licensing arrangements.

Does they mean they never read it before approving it?

lame-robot-hoax 5y ago

Why would it?

geoduck14 5y ago

I think that is a given

modriano 5y ago

Should they have delayed the emergency authorization of the vaccines until these 330,000 pages had all been reviewed and redacted? It would have cost hundreds of thousands of lives, but I can't see any benefit from that course of action.

gfodor 5y ago
Should they delay the FOIA release until these 330,000 pages had all been reviewed and redacted? I don’t think the answer to either of these questions are “no”, though ofc the standard could vary.
Reuzel 5y ago
emergency authorization != approval. These shenanigans show that the approval can't have been based on all the information. They should have delayed the approval, at least until Phase III trial officially ended.
- modriano 5y ago
  How many lives would that have cost, though, and for what benefit? The size of the sample that had already received the vaccine without issue made it basically impossible [0] for there to have been an unexpected danger. And without approval, the govt couldn't mandate federal employees take the vaccine, and that mandate has saved tens of thousands of lives. [0] https://en.m.wikipedia.org/wiki/Power_of_a_test https://en.m.wikipedia.org/wiki/Power_of_a_test

noduerme 5y ago

I'm assuming whoever made the decision read the summary. The majority of those "pages" are probably just raw data. Most of it is probably each experimental patient's temperature and blood pressure, each time they got checked, one page at a time.

mattkrause 5y ago

I'd bet that no one person has read all 329,000 pages, but I would bet that somebody looked at almost any given page. I'm hedging a bit on "any" because a New Drug Application is supposed to contain "the whole story of the drug." As a result, it includes the original and translated copies of any non-English publications related to the drug. It includes case reports for every participant who died during the trial, including in the placebo group. It includes information on related patents and licensing arrangements.